Maynard Um
-
-
-
-
-
-
-
Opus Genetics reports early positive data from gene therapy eye trial
-
-
-
-
-
-
-
Opus Genetics (IRD) Reiterated at Overweight by Cantor Fitzgerald on Positive Update
-
-
-
-
-
-
-
Opus Genetics outlines five gene therapy programs for retinal diseases
-
-
-
-
-
-
-
Citizens Reiterates Market Outperform Rating on Opus Genetics (IRD) Ahead of Trial Data Presentation
-
-
-
-
-
-
-
Craig-Hallum Reiterates Buy Rating on Opus Genetics (IRD): "continue to see significant upside opportunity"
-
-
-
-
-
-
-
B.Riley Starts Opus Genetics (IRD) at Buy
-
-
-
-
-
-
-
Opus Genetics receives FDA clearance for BEST1 gene therapy trial
-
471,031 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


